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Metastable conformations of the gp120 and gp41 envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and
simian immunodeficiency virus (SIV) must be maintained in the unliganded state of the envelope glycoprotein trimer. Binding
of gp120 to the primary receptor, CD4, triggers the transition to an open conformation of the trimer, promoting interaction with
the CCR5 chemokine receptor and ultimately leading to gp41-mediated virus-cell membrane fusion and entry. Topological lay-
ers in the gp120 inner domain contribute to gp120-trimer association in the unliganded state and to CD4 binding. Here we de-
scribe similarities and differences between HIV-1 and SIVmac gp120. In both viruses, the gp120 N/C termini and the inner do-
main-sandwich and layer 2 support the noncovalent association of gp120 with the envelope glycoprotein trimer. Layer 1 of the
SIVmac gp120 inner domain contributes more to trimer association than the corresponding region of HIV-1 gp120. On the
other hand, layer 1 plays an important role in stabilizing the CD4-bound conformation of HIV-1 but not SIVmac gp120 and thus
contributes to HIV-1 binding to CD4. In SIVmac, CD4 binding is instead enhanced by tryptophan 375, which fills the Phe 43
cavity of gp120. Activation of SIVmac by soluble CD4 is dependent on tryptophan 375 and on layer 1 residues that determine a
tight association of gp120 with the trimer. Distinct biological requirements for CD4 usage have resulted in lineage-specific dif-
ferences in the HIV-1 and SIV gp120 structures that modulate trimer association and CD4 binding.
The primate immunodeficiency viruses (PIVs) include the hu-man immunodeficiency viruses, HIV-1 and HIV-2, and the
simian immunodeficiency viruses (SIVs). In nature, HIV-1 and
HIV-2 infect humans, HIV-1-related SIVcpz viruses infect chim-
panzees, and SIV variants infect African monkeys (6, 23, 25, 43,
44). Based on phylogenetic evidence, SIV variants form the pri-
mary reservoir, with HIV-1 and HIV-2 resulting from zoonotic
cross-species transmissions within the last century or two (7, 24,
66). Clear lineage-specific genetic differences are observed be-
tween variants of SIV and also between these variants and their
more recent human crossovers (4, 7, 24, 66). Humans infected
with HIV-1 and HIV-2 and Asian macaques infected by certain
SIVs frequently develop life-threatening immunodeficiency
(AIDS) due to depletion of CD4-positive T lymphocytes (6, 11,
23, 32).
Entry of HIV-1 and SIV into the host cell is mediated by the
viral envelope glycoproteins, which are derived by proteolytic
cleavage of a trimeric, glycosylated gp160 envelope glycoprotein
precursor (2, 64). The resulting mature envelope glycoproteins,
the gp120 exterior envelope glycoprotein (SU) and the gp41 trans-
membrane envelope glycoprotein (TM), constitute a trimeric
complex on the virion surface that is anchored by the gp41 mem-
brane-spanning segments (8, 18, 71, 79). The gp120 exterior en-
velope glycoprotein is retained on the trimer via labile, noncova-
lent interactions with the gp41 ectodomain and perhaps with
other gp120 protomers (21, 29, 75, 77). The gp120 glycoprotein is
the most exposed element on the trimer and mediates binding to
the viral receptors on the host cell. Binding to the initial receptor,
CD4 (12, 36), triggers conformational changes in gp120 that pro-
mote its interaction with one of the chemokine receptors, usually
CCR5 (1, 10, 13–15, 19, 70, 73). CD4 binding also induces con-
formational changes in the assembled HIV-1 envelope glycopro-
tein trimer that result in a more “open” configuration in which a
helical heptad repeat (HR1) segment of the gp41 ectodomain is
exposed (22, 28, 38, 45, 67). Further conformational changes lead
to the formation of a gp41 six-helix bundle composed of the HR1
andHR2 heptad repeat regions, which provides the energy needed
to fuse the viral and target cell membranes (8, 46, 71).
The movement of the HIV-1 and SIV envelope glycoprotein
trimer from its unliganded state to the CD4-bound state must be
carefully regulated. Premature triggering of the metastable enve-
lope glycoprotein complex to downstream conformations results
in functional inactivation (22, 27, 28, 33, 34, 38). Because detailed
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structural information about gp120 in the unliganded HIV-1
trimer is lacking, only a rudimentary understanding of the se-
quence of events initiated byCD4binding exists. TheX-ray crystal
structure of an HIV-1 gp120 “core,” which lacks some of the
gp120 hypervariable loops, in complex with CD4 has been solved
(41, 54). In the CD4-bound state, the gp120 core consists of a
gp41-interactive inner domain, an outer domain that faces out-
ward on the assembled envelope glycoprotein trimer, and a
minidomain called the bridging sheet. CD4 is thought to initially
contact the outer domain of gp120 and to induce the formation of
the bridging sheet, a four-stranded antiparallel -sheet that inter-
acts directly with CD4 (41). Although the gp120 inner domain
does not contact CD4 (41, 54), conformational rearrangements
within this domain decrease the off rate of CD4 binding and thus
increase gp120-CD4 affinity (21). In the CD4-bound conforma-
tion, theHIV-1 gp120 inner domain consists of a-sandwich that,
along with the gp120 N and C termini, mediates the noncovalent
interaction with gp41 (29, 77); three topological layers (layers 1, 2,
and 3) in the inner domain emanate from this -sandwich and
were suggested to undergo rearrangement in the transition of
gp120 from the unliganded to the CD4-bound state (54). The
interaction of layer 1 and layer 2 within the HIV-1 gp120 inner
domain contributes in an indirect manner to CD4 binding (21).
Thus, gp120 refolds itself uponbinding toCD4,with the inner and
outer domains and bridging sheet brought into proximity at the
interface with CD4. An approximately 150-Å3 cavity between
HIV-1 gp120 andCD4 is bounded by Phe 43 of CD4, whichmakes
numerous contactswith conserved gp120 residues critical forCD4
binding (41). The gp120 residues that abut this “Phe 43 cavity” are
also highly conserved inHIV-1 strains, even thoughmany of these
residues do not contact CD4. Some of these cavity-lining residues
contribute to an aromatic array that helps stabilize the CD4-
bound conformation (21, 41, 54). Because changes in some inner
domain residues in layer 2 result in shedding of gp120 from the
envelope glycoprotein trimer, it has been suggested that CD4-
induced conformational changes involving the inner domain lay-
ers might promote partial release of the restraints that keep gp120
and gp41 in their unliganded conformation (21, 63).
Although HIV-1 and SIV use CD4 as a primary receptor, dif-
ferences exist between these PIV lineages. First, SIV is generally
less dependent on CD4 for infection than HIV-1 and can effi-
ciently infect cells with low levels of surface CD4 expression (17,
50, 51, 58–61, 65). The SIVsmm gp120 glycoproteins naturally
have a tryptophan 375 residue that is predicted to fill the Phe 43
cavity (39) and may contribute to the lower dependence on CD4.
In support of this hypothesis, substitution of tryptophan for serine
375, which is found in most HIV-1 strains (39), fills the Phe 43
cavity and allows HIV-1 gp120 to sample conformations closer to
the CD4-bound state spontaneously (76). Second, when soluble
CD4 (sCD4) orCD4-mimetic compounds trigger theCD4-bound
state on virions that are distant from a target cell, the infectivity of
HIV-1 decays with a half-life of 5 to 7 min at 37°C (27); by con-
trast, the sCD4-activated state of SIV is long-lived, allowing the
virus to infect CCR5-expressing cells hours after binding sCD4
(65). Intriguingly, the half-life of the sCD4-activated state of
HIV-1 was increased by changes in layer 1 of the inner domain
(21). Moreover, the impact of alterations in layers 1 and 2 on CD4
binding could be diminished by replacement of serine 375 with
tryptophan in HIV-1 gp120 (21). It is noteworthy that the disul-
fide loop in layer 1 of the gp120 inner domain is truncated in SIV
relative to that of HIV-1 (see below). These observations led us to
hypothesize that the interaction of layers 1 and 2 of the HIV-1
gp120 inner domain and the Phe 43 cavity-filling tryptophan 375
of SIV gp120 similarly serve to promote the CD4-bound confor-
mation and thus facilitate CD4 binding. A corollary of this hy-
pothesis is that the contribution of layers 1 and 2 to SIV gp120
interactionwithCD4will be less than that previously documented
for HIV-1 gp120 (21). Here we tested this hypothesis by investi-
gating the contributions of the gp120 inner-domain layers 1 and 2
and tryptophan 375 to the distinct biological properties of SIV.
For these studies, we chose the molecularly cloned and well-char-
acterized SIVmac239 (32, 35, 52) from the diverse group of SIVs.
The SIVmac239 envelope glycoproteins exhibit a dependence on
target cell CD4 levels similar to that of the HIV-1YU2 envelope
glycoproteins (5), which were studied in the previous mutagenic
analysis of the HIV-1 gp120 inner domain layers 1 and 2 (21).
Both SIVmac239 andHIV-2, which cause AIDS in Asianmonkeys
and humans, respectively, were derived from SIVsmm of sooty
mangabeys (11, 24, 31, 43, 44). Thus, SIVmac239, SIVsmm, and
HIV-2 are members of the same lineage of PIVs (24, 31, 39, 66).
MATERIALS AND METHODS
Modeling full-length SIV gp120.Modeling of the full-length SIVmac239
gp120 was done by using the X-ray crystal structure (PDB identifier
3JWD) of the ternary complex consisting of an HIV-1HXBc2 gp120 core
with intact N and C termini, two-domain CD4, and the antigen-binding
fragment of the human antibody 48d (54) as a template. Modeling was
performed on the Discovery Studio software platform (Accelrys Software,
Inc.). SIVmac239 gp120 glycoprotein modeling was based on protein se-
quence alignment with full-length HIV-1HXBc2 gp120, using the Modeler
(version 9) program in the Accelrys software package. The gp120 V4 vari-
able loop, consisting of the sequenceWSTEGSNNT,was disordered in the
X-ray crystal structure (54) and was added by modeling.
Cell lines. The 293T human embryonic kidney, Cf2Th canine thymo-
cyte (American Type Culture Collection), and TZM-bl cell lines (NIH
AIDSResearch and Reference Reagent Program)were grown at 37°Cwith
5% CO2 in Dulbecco’s modified Eagle’s medium (Invitrogen) containing
10% fetal bovine serum (Sigma) and 100 g/ml of penicillin-streptomy-
cin (Mediatech, Inc.). Cf2Th cells stably expressing human CD4 and
CCR5 (42) were grown inmedium supplementedwith 0.4mg/ml of G418
(Invitrogen) and 0.15 mg/ml of hygromycin B (Roche Diagnostics).
Cf2Th-CCR5 cells were grown in medium supplemented with 0.4 mg/ml
of G418 (Invitrogen). The TZM-bl cell line is a HeLa cell line stably ex-
pressing high levels of CD4 and CCR5 and possessing an integrated copy
of the luciferase gene under the control of the HIV-1 long terminal repeat
(57).
Site-directed mutagenesis. Mutations were introduced individually
or in combination into the previously described vector expressing the
SIVmac239 envelope glycoproteins (pSIVmac239) (47, 48). Site-directed
mutagenesis was performed using the QuikChange II XL site-directed
mutagenesis protocol (Stratagene). The presence of the desiredmutations
was determined by automated DNA sequencing. The numbering of the
SIVmac239 and HIV-1 envelope glycoprotein amino acid residues is
based on that of the prototypic HXBc2 strain of HIV-1, where 1 is the
initial methionine (37).
Immunoprecipitation and CCR5 binding of envelope glycopro-
teins. For pulse-labeling experiments, 3 105 293T cells were cotransfected
by the calcium phosphatemethod with pLTR-Tat and the pSIVmac239 vec-
tor expressing the SIVmac239 envelope glycoproteins. One day after
transfection, cells were metabolically labeled for 16 h with 100 Ci/ml
[35S]methionine-cysteine (35S] protein labeling mix; Perkin-Elmer) in
Dulbecco’s modified Eagle’s medium lacking methionine and cysteine
and supplemented with 5% dialyzed fetal bovine serum. Cells were sub-
sequently lysed in RIPA buffer (140 mM NaCl, 8 mM Na2HPO4, 2 mM
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NaH2PO4, 1%NP-40, and 0.05% sodium dodecyl sulfate [SDS]). Precip-
itation of radiolabeled SIVmac239 envelope glycoproteins from cell ly-
sates or medium was performed with a mixture of sera from SIV-infected
macaques. Alternatively, medium containing radiolabeled envelope pro-
teins was immunoprecipitated with increasing amounts of CD4-Ig for 1 h
at 37°C in the presence of 50 l of 10% protein A-Sepharose (Amersham
Biosciences).
For CCR5 binding, normalized amounts of radiolabeled SIVmac239
gp120 envelope glycoproteins were incubated in the presence or absence
of 200 nm of sCD4 for 1 h at 37°C. Subsequently, 2  106 Cf2Th-CCR5
cells were added for an additional 1 h at 37°C and washed twice with
phosphate-buffered saline (PBS) prior to cell lysis in RIPA buffer. Cell
lysates were immunoprecipitated with a mixture of sera from SIV-in-
fected macaques. All samples were loaded on NuPAGE Novex Bis-Tris
polyacrylamide gels (Invitrogen) and analyzed by autoradiography and by
using a PhosphorImager (Molecular Dynamics). For CD4-Ig and CCR5
immunoprecipitations, samples were analyzed under nonreducing con-
ditions as previously described (20).
Cell-based ELISA.Detection of trimeric envelope glycoproteins at the
surface of COS-1 cells was performed by cell-based ELISA, as described
previously (27). Briefly, COS-1 cells were seeded in 96-well plates (2 104
cells per well) and transfected the next day with 0.15 g of a plasmid
expressing the envelope glycoproteins and 0.01 g of a Tat-expressing
plasmid per well using the standard polyethylenimine (PEI) (Polyscience
Inc., Pennsylvania) transfection method. Two days later, cells were
washed twice with blocking buffer (10 mg/ml nonfat dry milk, 1.8 mM
CaCl2, 1 mM MgCl2, 25 mM Tris, pH 7.5, and 140 mM NaCl) and then
incubated for 1 h at room temperature with a 1/2,000 dilution of heat-
inactivated serum from SIV-infected monkeys (a kind gift from Norman
Letvin, Beth Israel DeaconessMedical Center). A horseradish peroxidase-
conjugated antibody specific for the Fc region of human IgG (Pierce) was
then incubated with the samples for 45 min at room temperature. Cells
werewashed 5 timeswith blocking buffer and 5 timeswithwashing buffer.
Horseradish peroxidase (HRP) enzyme activity was determined after the
addition of 30l per well of a 1:1 mix ofWestern Lightning oxidizing and
luminol reagents (Perkin Elmer Life Sciences). Light emission was mea-
sured with an LB 941 TriStar luminometer (Berthold Technologies).
Recombinant luciferase viruses.Recombinant viruses containing the
firefly luciferase genewere produced by calciumphosphate transfection of
293T cells with the HIV-1 proviral vector pNL4.3 EnvLuc and the plas-
mid expressing the wild-type or mutant SIVmac239 envelope glycopro-
teins at a ratio of 2:1. Two days after transfection, the cell supernatants
were harvested; the reverse transcriptase activities of all viruses were mea-
sured as described previously (62). The virus-containing supernatants
were stored in aliquots at80°C.
Infection by single-round luciferase viruses.Cf2Th-CD4-CCR5 tar-
get cells were seeded at a density of 5 103 cells/well in 96-well luminom-
eter-compatible tissue culture plates (Dynex) 24 h before infection. Re-
combinant viruses (10,000 reverse transcriptase units) in a final volume of
100l were then added to the target cells, followed by incubation for 48 h
at 37°C; the mediumwas then removed from each well, and the cells were
lysed by the addition of 30 l of passive lysis buffer (Promega) and three
freeze-thaw cycles. An EG&G Berthold microplate luminometer, LB 96V,
was used tomeasure the luciferase activity of eachwell after the addition of
100 l of luciferin buffer (15 mMMgSO4, 15 mM KPO4 [pH 7.8], 1 mM
ATP, and 1 mM dithiothreitol) and 50 l of 1 mMD-luciferin potassium
salt (BD Pharmingen).
Cell-cell fusion. To assess cell-to-cell fusion, 3 105 293T cells were
cotransfected by the calcium phosphate method with an HIV-1 Tat-ex-
pressing plasmid, pLTR-Tat, and the pSIVmac239 vector expressing the
SIVmac239 envelope glycoproteins. Two days after transfection, 3 104
293T cells were added to TZM-bl target cells that were seeded at a density
of 3  104 cells/well in 96-well luminometer-compatible tissue culture
plates (Dynex) 24 h before the assay. Cells were coincubated for 6 h at
37°C, after which they were lysed by the addition of 30 l of passive lysis
buffer (Promega) and three freeze-thaw cycles. Luciferase activity in each
well was measured as described above.
RESULTS
Comparison of the HIV-1 and SIV gp120 inner domains. We
wished to investigate the function of the inner domain of SIVmac
gp120. Because a structure of SIV gp120 with the complete inner
domain is not available (9), we modeled the SIVmac239 gp120
envelope glycoprotein based on the X-ray crystal structure of the
HIV-1 gp120 core with intact N and C termini, bound to soluble
CD4 and a neutralizing antibody fragment (54). This X-ray crys-
tallographic study revealed the structure of the complete HIV-1
gp120 inner domain (54) (Fig. 1A). A key component of the inner
domain, a seven-stranded -sandwich, serves as a point of depar-
ture for the gp120 N and C termini, which meander toward the
viral membrane. The -sandwich and the gp120 terminal strands
have been implicated in the noncovalent association of gp120with
gp41 (21, 29, 77). Projecting from the -sandwich toward the
FIG 1 Structure of the inner domain of HIV-1 gp120 andmodeled SIV gp120
in the CD4-bound conformation. (A) The structure of the HIV-1HXBc2 gp120
corewithN/C termini in the CD4-bound state (54) is shown from the perspec-
tive of CD4 (left panel) and from the approximate perspective of the envelope
glycoprotein trimer axis (right panel). The outer domain (OD) of gp120 is
colored yellow. The N and C termini are colored cyan. The components of the
gp120 inner domain (ID) are the -sandwich (red) and three loop-like exten-
sions: layer 1 (magenta), layer 2 (green), and layer 3 (orange). The 20-21
strands of gp120 (blue) project from the outer domain and, in the CD4-bound
conformation, compose two of the strands of the four-stranded bridging sheet.
The other two strands of the bridging sheet are derived from the distal portion
of layer 2. The location of the Phe 43 cavity is indicated by a red asterisk. A
close-up view of the interactions of the inner domain layer 1 and layer 2 from
HIV-1 gp120 (B) or a modeled SIV gp120 glycoprotein (C) is shown. The
perspective in panels B andC is rotated approximately 25° in the counterclock-
wise direction around the Z axis from the perspective in the right part of panel
A. The cysteine residues that form a disulfide bond in layer 1 are colored
yellow, and some of the layer 1 and layer 2 residues implicated in layer 1-layer
2 interaction in HIV-1 gp120 (21) are colored blue. The 0 helix in layer 1 and
the 1 helix in layer 2 are labeled.
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target cell membrane are three excursions that compose the rest of
the inner domain. These excursions form three topological layers
(“layers 1, 2, and 3”) that have been proposed to change confor-
mation as gp120 undergoes the transition from the unliganded
state to the CD4-bound state (54). Changes in layer 2 can decrease
the stable association of HIV-1 gp120 with the envelope glycopro-
tein trimer and result in shedding of gp120 (21). The interaction
of layers 1 and 2 in the HIV-1 gp120 inner domain strengthens
gp120-CD4 binding by reducing the off rate (21).
The SIVmac239 gp120 primary amino acid sequence was
aligned with that of HIV-1 gp120. The nine intrachain disulfide
bonds in HIV-1 gp120 glycoproteins are conserved in all PIV
gp120 glycoproteins, assisting the alignment of the HIV-1 and
SIVmac239 gp120 sequences (37, 39). The alignment of the se-
quences of the inner domain (layer 1, layer 2, -sandwich, and N
and C termini) and Phe 43 cavity-lining residues relevant to this
study is shown in Fig. 2. Layer 1 is truncated in the gp120 glyco-
proteins of HIV-2 and most monkey SIV strains compared with
that of HIV-1/SIVcpz strains (Fig. 2 and 3). Notably, the only
exceptions are the gp120s of the SIVgsn/SIVmon/SIVmus clade,
which are thought to provide the env gene of the recombinant
SIVcpz that gave rise to HIV-1 (4, 25, 66) (Fig. 3). Modeling sug-
gests that the 0 helix in the SIVmac239 gp120 inner domain is
shorter than that in HIV-1 gp120 (compare Fig. 1B and C). Inter-
estingly, as observed for HIV-1 gp120, the conserved residues Trp
69, Asp 107, and Leu 111 are predicted to be located at the inter-
face of layers 1 and 2 of SIVmac239 gp120 (compare Fig. 1B and
C). However, a fourth residue, His 66, at the layer 1-layer 2 inter-
face ofHIV-1 gp120, lacks a counterpart in SIV gp120 as a result of
the truncation of layer 1. Of note, HIV-1/SIVcpz gp120 glycopro-
teins, which invariably have a histidine at position 66, also have a
proline at position 212 (Fig. 3); this proline makes stacking inter-
actions with His 66 and helps to stabilize the CD4-bound confor-
mation (21, 34, 54). Interestingly, the gp120 glycoproteins of the
HIV-2/SIVsmm lineage, which includes SIVmac239, lack a coun-
FIG 2 Alignment of HIV-1 and SIVmac239 gp120 regions. The primary amino acid sequences of specific regions of HIV-1 (accession number K03455), SIVcpz
(accession number AY169968), and SIVmac239 (accession number M33262) are aligned. Sequence identity is indicated by a solid vertical line, and amino acid
residues that are conserved are connected by a dotted vertical line. Gaps in the sequence are indicated by dashes. Residue numbering is based on that of theHXBc2
strain of HIV-1 (37).
FIG 3 Evolution of gp120 changes in PIVs. The phylogenetic relationship of
envelope glycoprotein sequences of the PIVs is shown, based on previous stud-
ies (4, 7, 66, 68). The evolutionary distances in this tree are approximate. The
disulfide loop (DSL) length of layer 1 in the gp120 inner domain is shown in
the first column. The identities of residues 66, 212, and 375 in gp120 are shown
in the other columns. A dash indicates the absence of a corresponding residue
in the gp120 glycoprotein of the indicated PIV.
SIV gp120 Elements Modulate CD4 Triggering
September 2012 Volume 86 Number 17 jvi.asm.org 8977
terpart of His 66 and also lack a proline residue at position 212; in
the HIV-2/SIVsmm lineage, residue 212 is an alanine, serine, or
threonine residue (39) (Fig. 2 and 3). Thus, in HIV-2/SIVsmm
strains, fewer predicted layer 1-layer 2 interactions are available to
promote/stabilize the CD4-bound conformation of gp120 than in
HIV-1/SIVcpz strains.
The above analysis predicts that substantial differences exist
between the inner domain layer 1 of HIV-1 and SIVmac239
gp120. Although the primary sequences of the other gp120 inner
domain and N/C-terminal elements diverge between HIV-1 and
HIV-2/SIVsmm lineages, no major insertions/deletions were ob-
served in these regions of PIV envelope glycoproteins (Fig. 2).
CD4 binding depends upon the 3 helix of HIV-1 gp120, and
the adjacent 16 strand flanks the Phe 43 cavity (41). The side
chain of residue 375 is oriented toward the Phe 43 cavity, and thus
large residues have the potential to occupy the cavity (76). Com-
parison of the gp120 16 sequences from different PIVs indicates
that HIV-2 and the SIVs of monkeys and apes have large residues
(Trp,Met, Tyr, His, and Phe) at position 375 that likely fill the Phe
43 cavity (39) (Fig. 2 and 3). HIV-1 strains in the N and O groups
also have these large residues at position 375 (Fig. 3). In contrast,
the HIV-1 strains in groupM, themajor group of HIV-1, have the
smaller Ser 375, which allows the existence of an “empty” Phe 43
cavity. Apparently, gp120 residue 375 has evolved from trypto-
phan in most monkey SIVs to other large residues (Met, His, Tyr,
and Phe) in most ape SIVs and in group N and O HIV-1. Evolu-
tion of the group M HIV-1 from SIVcpzPtt (66) favored a serine
residue at position 375. Based on the CD4-binding phenotypes of
HIV-1 gp120mutants with different substitutions at Ser 375 (76),
the phylogenetic changes in residue 375 accompanying the evolu-
tion of the group M HIV-1 envelope glycoproteins would be ex-
pected to decrease the tendency to assume the CD4-bound con-
formation.
Effect of gp120 innerdomainchangesonprocessingandsub-
unit association of the SIVmac239 envelope glycoproteins. The
contribution of the gp120 inner domain to the structure and func-
tion of the SIVmac239 envelope glycoproteins was evaluated by
studying the phenotypes of a panel of mutant envelope glycopro-
teins (Table 1). Proteolytic processing of the envelope glycopro-
tein precursor and the noncovalent association of the gp120 exte-
rior envelope glycoprotein with the gp41 transmembrane
envelope glycoprotein in the trimer were evaluated. Some of the
amino acid changes (W96A and L225A) in the inner domain
-sandwich severely affected precursor processing; these mutants
were defective in multiple envelope glycoprotein functions, sug-
gesting that they may experience folding problems.
Several changes in the SIVmac239 gp120 inner domain de-
creased the association of gp120 with the envelope glycoprotein
trimer (Fig. 4 and Table 1). Multiple changes (L52A, T56A, R61A,
D62A, T63A,W69L,W69F, T72A, andQ73A) in layer 1 disrupted
gp120-trimer association. These results were noteworthy, since
relatively few changes in layer 1 of HIV-1 gp120 exerted effects on
subunit association (21) (Fig. 5A). Alteration of several layer 2
residues affected the association of the SIVmac239 gp120 glyco-
protein with the trimer, consistent with the phenotypes of layer 2
mutants of the HIV-1 gp120 glycoprotein (21) (Fig. 4 and 5B and
Table 1).However, changes in particular layer 2 residues (Gln 103,
Trp 109, and Ala 212) affected SIVmac239 gp120-trimer associa-
tion differently than alteration of the equivalent residue in HIV-1
gp120 (21). Likewise, although several changes in the SIVmac239
gp120 inner domain -sandwich and N/C termini resulted in sig-
nificant shedding of gp120 from the trimer, the association of
SIVmac239 gp120 with the trimer was less sensitive than the
HIV-1 gp120-trimer association to changes in Tyr 40, Val 85, Ala/
Leu 86, and Val 89. These observations suggest that layer 1 con-
tributes significantly to the stability of the SIV envelope glycopro-
tein trimer, in contrast to layer 1 of HIV-1 gp120. Layer 2, the
-sandwich, and the N/C termini of both HIV-1 and SIV gp120
support gp120-trimer association, although the contribution of
particular residues to this property appears to differ between these
viruses.
Interaction of mutant SIVmac239 envelope glycoproteins
with CD4.Alteration of the interface between layers 1 and 2 of the
HIV-1 gp120 inner domain has been shown to decrease CD4
binding, revealing an important mechanism whereby HIV-1
gp120 regulates CD4-induced conformational rearrangement and
achieves a reduction in the off rate (21, 34, 54). To investigate the
contribution of the inner domain of SIV gp120 to CD4 binding,
the CD4-binding abilities of the panel of SIVmac239 gp120 mu-
tants were examined.Wild-type andmutant SIVmac239 envelope
glycoproteins were transiently expressed in 293T cells, which were
radiolabeled for 16 h. The amount of radiolabeled gp120 glyco-
proteins shed into the cell medium was normalized by immuno-
precipitation with polyclonal serum from SIV-infected macaques
before assessing the ability to bind CD4-Ig. Notably, none of the
changes in the disulfide-bonded loop of the SIV gp120 layer 1
significantly decreased CD4-Ig binding (Fig. 5C, Fig. 6A and B,
and Table 1). TheW69L andW69F changes, which decrease CD4
binding of the HIV-1 gp120 glycoprotein (21), did not signifi-
cantly diminish the interaction of SIVmac239 gp120with CD4-Ig.
Only two changes, E47A and L52A, which affect the layer 1 strand
that is N-terminal to the disulfide loop, resulted in a decrease in
CD4-Ig binding; the L52A change in the HIV-1 gp120 glycopro-
tein has been previously shown to decrease CD4-Ig binding (21).
These results suggest that the disulfide-bonded loop in layer 1 of
the SIV gp120 inner domain makes less of a contribution to CD4
binding than the corresponding region of HIV-1 gp120 (Fig. 5C).
A previous study (21) showed that the phenotypic effects of the
changes in His 66 and Trp 69 in layer 1 of the HIV-1 gp120 glyco-
protein on CD4 binding were eliminated by the S375W change,
which fills the Phe 43 cavity (76). We hypothesized that the pres-
ence of a tryptophan residue at position 375 in the SIVmac239
gp120 glycoprotein likewisediminished thepotential contributionof
layer1-layer2 interactions toCD4binding.Totest thishypothesis,we
examined the CD4-binding ability of an SIVmac239W375Smutant
gp120 that, in some cases, had additional changes predicted to de-
crease layer 1-layer 2 interaction. The W375S change decreased the
interaction of the SIVmac239 gp120 glycoprotein with CD4-Ig (Ta-
ble 1; see also Fig. S1 in the supplemental material). In combination
with theW375Salteration, theW69Lchange in layer1and theW109I
change in layer2 reducedCD4-Igbinding further; ofnote,neither the
W69L change nor theW109I change significantly decreased CD4-Ig
binding in the context of the wild-type SIVmac239 gp120 glycopro-
tein (Table 1). Thus, the presence of the Phe 43 cavity-filling trypto-
phan 375 residue diminishes the contribution of inner domain layer
1-layer 2 interactions to CD4 binding.
The majority of SIVmac239 gp120 inner domain changes that
decreased CD4-Ig binding involved layer 2 residues. Changes in
residues Asp 107, Leu 111, Trp/Phe 112, and Ile/Phe 215 decreased
CD4 binding in both HIV-1 and SIVmac239 gp120 glycoproteins
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TABLE 1 Phenotypes of SIVmac239 gp120 mutantsa
Mutation(s)b Residue location Association indexc Processing indexd Relative infectivitye Cell-to-cell fusionf CD4-Ig bindingg
None 1.00 1.00 1.00 1.00 1.00
V36A N terminus 0.26 0.98 0.46 1.29 1.88
Y40A N terminus 0.81 1.20 0.48 0.76 1.30
N47A N terminus 1.05 0.56 0.26 1.25 0.53
L52A Layer 1 0.41 0.70 0.04 0.97 0.54
T56A Layer 1 0.38 0.72 0.10 0.88 0.73
R61A Layer 1 0.28 0.82 0.23 0.67 1.03
R61S Layer 1 0.36 0.93 0.01 1.20 1.38
D62A Layer 1 0.12 0.49 0.01 0.88 1.17
T63A Layer 1 0.20 1.20 0.10 1.04 1.60
W69L Layer 1 0.34 0.58 0.02 0.89 0.96
W69F Layer 1 0.23 0.84 0.01 1.02 1.38
T72A Layer 1 0.38 0.80 0.11 1.14 0.83
Q73A Layer 1 0.27 0.67 0.03 1.09 0.82
P76A Layer 1 0.94 0.81 0.01 0.01 0.97
N78A Layer 1 0.96 0.89 0.01 0.08 0.67
G79S Layer 1 1.19 0.85 0.47 0.91 0.61
E83A -Sandwich 0.83 0.15 0.17 0.85 NA
A85G -Sandwich 1.14 0.93 0.33 0.60 0.54
L86V -Sandwich 0.93 1.15 1.09 0.99 1.23
V89A -Sandwich 0.74 1.34 0.42 0.95 1.53
T90A -Sandwich 0.65 0.48 0.27 0.80 0.47
E91A -Sandwich 0.75 4.52 0.77 0.82 1.24
W96A -Sandwich 0.37 0.07 0.02 0.01 NA
Q103A Layer 2 0.17 0.78 0.01 0.94 0.01
D107A Layer 2 0.48 0.88 0.01 0.87 0.46
W109I Layer 2 0.96 0.95 0.45 0.53 0.85
L111A Layer 2 0.56 0.83 0.07 0.85 0.49
F112A Layer 2 0.07 0.75 0.01 1.17 0.23
I116A Layer 2 0.17 1.04 0.07 1.98 1.02
A212P Layer 2 0.09 1.10 0.03 ND 1.32
F215A Layer 2 0.25 0.14 0.01 0.64 0.01
R216A Layer 2 0.62 0.30 0.02 0.01 0.23
Y217A Layer 2 0.58 0.10 0.01 0.47 NA
P221A Layer 2 0.42 0.57 0.06 0.18 0.46
Y223A -Sandwich 0.33 0.14 0.22 1.10 NA
L225A -Sandwich 0.52 0.04 0.01 0.21 NA
L226A -Sandwich 0.65 0.15 0.14 0.99 NA
F233A -Sandwich 0.53 0.06 0.01 0.01 NA
W375S Phe 43 cavity 0.76 1.09 0.24 0.41 0.48
K487A C terminus 0.34 0.08 0.03 1.07 NA
V491A C terminus 0.37 0.26 0.44 1.28 0.22
I494A C terminus 0.07 0.37 0.01 0.84 1.88
L496A C terminus 0.14 0.59 0.28 1.17 1.52
W69L/W375S Layer 1/Phe 43 0.32 1.36 0.02 0.78 0.27
D107A/W375S Layer 2/Phe 43 0.44 1.47 0.03 0.97 0.37
W109I/W375S Layer 2/Phe 43 0.65 1.12 0.29 0.09 0.26
L111A/W375S Layer 2/Phe 43 0.87 1.58 0.03 0.58 0.27
a Values presented in this table represent the means of data from at least two independent experiments, with experimental variation typically not more than 20% of the value reported.
b The numbering of the SIVmac239 gp120 envelope glycoprotein amino acid residues is based on that of the prototypic HXBc2 strain of HIV-1, where 1 is the initial methionine
(37). The mutations result in the substitution of the amino acid residue shown on the right for the amino acid residue shown on the left of the number; for example, W69L
indicates a substitution of a leucine residue for the tryptophan residue at position 69.
c The association index is a measure of the ability of the mutant gp120 molecule to remain associated with the envelope glycoprotein complex on the expressing cell relative to that
of the wild-type envelope glycoproteins. The association index is calculated as follows: association index ([mutant gp120]cell [wild-type gp120]supernatant)/
([mutant gp120]supernatant [wild-type gp120]cell).
d The processing index is a measure of the conversion of the mutant gp160 envelope glycoprotein precursor to mature gp120 relative to that of the wild-type envelope glycoproteins.
The processing index was calculated by the following formula: processing index ([total gp120]mutant [gp160]wild-type)/([gp160]mutant [total gp120]wild-type).
e Relative infectivity was assessed by infecting Cf2Th-CD4/CCR5 cells with similar amounts of recombinant HIV-1 pseudotyped with wild-type and mutant SIVmac239 envelope
glycoproteins, normalized according to reverse transcriptase (see Materials and Methods). The ratio of mutant/wild-type virus infectivity is reported.
f Cell-cell fusion ability was assessed by coincubation for 6 h at 37°C of 293T cells expressing the SIVmac239 envelope glycoprotein variants with the reporter TZM-bl cells, as
described in Materials and Methods. ND, not determined.
g Normalized amounts of radiolabeled wild-type and mutant gp120 glycoproteins were incubated with 13 nM CD4-Ig for 1 h at 37°C. The immunoprecipitates were washed, run on
SDS-polyacrylamide gels, and analyzed by densitometry. NA, not applicable, because the levels of gp120 secreted into the supernatant for these mutants were not sufficient to assess
CD4 binding.
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(Table 1) (21). The Q103A change decreased CD4-Ig binding of
SIVmac239 gp120 but not that of HIV-1 gp120. Conversely,
changes in Ile/Trp109, Leu/Ile 116, and Pro/Ala 212 decreased
CD4 binding of HIV-1 gp120 but not that of SIVmac239 gp120.
Thus, layer 2 changes can affect the CD4-binding affinity of both
HIV-1 and SIVmac239 gp120 glycoproteins, but the contribution
of individual layer 2 residues to CD4 binding may differ between
the two viruses (Fig. 5D).
Abilities of mutant envelope glycoproteins to interact with
CCR5. A functionally critical consequence of CD4 binding to the
HIV-1 and SIV gp120 glycoproteins is the induction of conforma-
tional changes that lead to the binding of the chemokine receptor
CCR5 or CXCR4 (1, 10, 13–15, 19, 70, 74). We analyzed whether
introducing changes in the interface between layers 1 and 2 in the
SIVmac239 gp120 inner domain affected CCR5 recognition. Ra-
diolabeled wild-type and mutant SIV gp120 glycoproteins were
incubated in the presence or absence of sCD4 for 1 h at 37°C prior
to incubation with cells expressing the CCR5 coreceptor for 1 h at
37°C. After washing and lysis of the cells, bound gp120 was de-
tected by immunoprecipitation. Consistent with a modest effect
of the D107A and L111A changes in layer 2 on CD4 binding, only
slight decreases in CCR5 recognition were observed for these mu-
tants in the presence of sCD4 (Fig. 6A and C).
Function of mutant SIV envelope glycoproteins. The wild-
type and mutant SIVmac239 envelope glycoproteins were as-
sessed for the ability to mediate cell-cell fusion with cells express-
ing both CD4 and CCR5, as ameasure of their functionality.With
the exception of only 8 mutants (P76A, N78A, W96A, R216A,
P221A, L225A, F233A, andW109I/W375S), the SIVmac239 enve-
lope glycoprotein mutants mediated efficient cell-cell fusion (Fig.
7A andTable 1). Thus, inmost cases, the introduction of the inner
domain changes did not abolish the abilities of the SIV envelope
glycoproteins to bind receptors and mediate membrane fusion.
We also evaluated the abilities of the panel of SIVmac239 en-
velope glycoprotein mutants to support the infection of cells ex-
pressing CD4 and CCR5. As expected, the mutants exhibiting de-
creased gp120-trimer association were significantly attenuated in
the ability to mediate cell-free virus infection (Fig. 7B and Table
1). Themajority of thesemutant envelope glycoproteinsmediated
cell-cell fusion much more efficiently than cell-free virus infectiv-
ity. This phenotype has been previously observed for HIV-1 enve-
lope glycoprotein mutants that exhibit decreased gp120-trimer
FIG 4 Precursor processing and gp120-trimer association of selected
SIVmac239 envelope glycoprotein mutants. Cell lysates and supernatants
(SN) of 35S-labeled cells transiently expressing the SIVmac239 wild-type
and indicated mutant envelope glycoproteins were precipitated with serum
from an SIV-infected macaque. The precipitated proteins were loaded onto
NuPAGE Novex Bis-Tris polyacrylamide gels and analyzed by autoradiog-
raphy and densitometry.
FIG 5 Residues important for gp120-trimer association and CD4 binding. Layer 1 and Layer 2 of HIV-1 gp120 (54) and the modeled SIVmac239 gp120 are
shown from the same perspective as those in Fig. 1, B and C. In panels A and B, the ribbon and side chain residues that were altered in this and a previous study
(21) are colored according to the gp120-trimer association index (Red: association index 0.5 andGreen: association index 0.7). In panels C andD, the ribbon
and side chain residues are colored according to CD4-Ig binding ability (Red: relative CD4-Ig binding 0.5 and Green: relative CD4-Ig binding 0.5).
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association (21, 77); because the time between envelope glycopro-
tein synthesis and engagement of the target cell is much longer in
the virion infectivity assay than in the cell-cell fusion assay, the
former assay is more sensitive to decreases in the stability of
gp120-trimer association.
Two of the SIVmac239 layer 1 mutants, P76A and N78A, did
not mediate efficient cell-cell fusion or virus entry yet exhibited
processing and association indices and CD4-Ig binding values
similar to those of the wild-type SIVmac239 envelope glycopro-
tein. Thesemutants are capable of engaging the CD4 receptor, but
they exhibit decreased cell surface expression that might contrib-
ute to their decreased functionality (Fig. 7C). The analogous mu-
tants in the HIV-1 envelope glycoproteins were not as attenuated
in cell-cell fusion activity (21).
SIV envelope glycoprotein determinants of sCD4 activation
of entry. Unlike HIV-1 envelope glycoproteins, which undergo a
relatively short-lived activation by sCD4 treatment (27), the
SIVmac239 envelope glycoproteins assume a long-lived, activated
state after sCD4 binding (3, 65). We examined whether the gp120
structural elements that differ between HIV-1 and SIV might ex-
plain these distinct responses to sCD4. Specifically, we tested
whether changes in the Phe 43 cavity-filling residue, Trp 375, and
layer 1 of the inner domain affected the response of viruses with
the SIVmac239 envelope glycoproteins to sCD4. sCD4 activation
of entrymediated by thewild-type SIVmac239 envelope glycopro-
teins was evident on CD4 CCR5	 target cells (Fig. 8B) and to a
lesser extent on CD4	 CCR5	 target cells (Fig. 8A). The W375S
envelope glycoproteins were minimally activated by sCD4 for in-
fection of CD4 CCR5	 target cells (Fig. 8B) and were inhibited
by sCD4 during infection of CD4	CCR5	 cells (Fig. 8A). Soluble
CD4 activation of infection of both CD4 CCR5	 and CD4	
CCR5	 cells was eliminated by the R61A change in layer 1 (Fig. 8A
and B). Thus, sCD4 activation of the SIVmac239 envelope glyco-
proteins is dependent upon the Phe 43 cavity-filling Trp 375 res-
idue and on elements in layer 1 of the inner domain.
DISCUSSION
HIV-1 and HIV-2/SIV share ancestry and many properties, in-
cluding the ability to infect CD4	 CCR5	 T lymphocytes, mono-
cytes/macrophages, and microglia. Low-resolution cryoelectron
tomograms of HIV-1 and SIV virions indicate that the envelope
glycoprotein trimers of these viruses exhibit a similar overall ar-
chitecture (45, 72, 73, 78, 79, 80). A recent study has shown that
the HIV-1 gp120 core has a propensity to assume the CD4-bound
conformation spontaneously once the V1/V2 and V3 variable
loops are removed (40). Thus, in the unliganded envelope glyco-
protein complex, gp120 must retain a stable association with the
trimer but must also be restrained from sampling downstream
conformations, such as the CD4-bound state. Some of the HIV-1
gp120 elements (N/C termini, inner domain -sandwich and
layer 2, and V3 [in primary strains]) that contribute to the stable
association of gp120 with the envelope glycoprotein trimer have
been characterized (21, 30, 54, 75, 77). Here we have provided
evidence that the SIVmac239 gp120 N/C termini and inner do-
main -sandwich and layer 2 also contribute to gp120-trimer as-
sociation. Thus, the global architecture of the envelope glycopro-
tein structures that govern gp120-trimer association is likely
shared by HIV-1 and SIVmac239. Some differences exist in the
trimer association phenotypes associated with changes in partic-
ular residues within these elements of HIV-1 and SIV gp120, sug-
gesting that there may be subtle differences in the specific struc-
tural relationships between the envelope glycoproteins of these
virus lineages.
Our study highlights two structural elements that differ be-
tween the HIV-1 and SIV gp120 exterior envelope glycoproteins,
i.e., layer 1 of the inner domain and the Phe 43 cavity-lining resi-
due 375. We investigate the function of these elements in the
SIVmac239 envelope glycoproteins, and we show that these ele-
FIG 6 Binding of soluble SIVmac239 gp120 glycoproteins to CD4-Ig and
CCR5. Normalized amounts of radiolabeled wild-type and mutant gp120 gly-
coproteins were incubated with 13 nM CD4-Ig for 1 h at 37°C (A and B). The
precipitates were washed, run on SDS-polyacrylamide gels, and analyzed by
densitometry. Representative results from at least five independent experi-
ments are shown. (C) Similar amounts of radiolabeled gp120 glycoproteins
were incubated in the absence (gray bars) or presence (white bars) of 200 nM
sCD4 prior to addition to cells expressing CCR5. After 1 h at 37°C, the amount
of bound mutant gp120 was determined and normalized to the observed
amount of bound wild-type (wt) gp120. Incubation with sCD4 increased the
binding of wt SIVmac239 gp120 to CCR5 by 8-fold. The data shown represent
the means
 SEM of four independent experiments.
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ments interdependently determine phenotypes related to CD4
binding. Relative to layer 1 of HIV-1 gp120, the SIVmac239 gp120
layer 1 plays a more prominent role in maintaining gp120-trimer
association and isminimally involved in promoting CD4 binding.
HIV-2/SIVsmm gp120 glycoproteins, like those of most monkey
SIVs, typically have a tryptophan residue at position 375 (39). In
HIV-1, substitution of tryptophan for serine 375, which is well
conserved in the major group of HIV-1, results in spontaneous
sampling of a conformation closer to the CD4-bound state (76).
The S375WHIV-1mutant binds CD4more efficiently and exhib-
its increased sensitivity to sCD4-induced shedding of gp120 and
neutralization (21, 76). These observations suggested the hypoth-
esis that relative to HIV-1 gp120, the HIV-2/SIVsmm gp120 gly-
coproteins, by virtue of the Phe 43 cavity-filling Trp 375, might
naturally exhibit a greater propensity to sample the CD4-bound
conformation. We found that a W375S change in the SIVmac239
envelope glycoproteins decreased CD4 binding and eliminated
the enhancing effect of sCD4 on infection of CD4	 CCR5	 and
CD4CCR5	 target cells (3, 65). This sCD4-induced activation of
SIVmac239 infectionwas also dependent on the integrity of gp120
layer 1. Moreover, some additional decrease in CD4 binding was
associated with SIV gp120 layer 1 mutants in the context of the
W375S, but not the wild-type, SIVmac239 envelope glycopro-
teins. The cooperative influence of both residue 375 and layer 1 in
determining CD4 binding and its consequences is supported by
the converse studies of the HIV-1 envelope glycoproteins. The
H66A and W69L layer 1 changes decreased the CD4-binding af-
finity of HIV-1 gp120 but had no effect on CD4 binding of an
S375W HIV-1 mutant (21). Moreover, changes in these HIV-1
layer 1 residues, particularly in combination with the S375W
change, allowed the formation of a longer-lived activated interme-
diate upon sCD4 binding, closer to the sCD4-induced phenotype
observed for SIV (21). Thus, the gp120 inner domain layer 1 and
residue 375 exert reciprocal influences on the affinity of CD4
binding and the stability of the CD4-activated state.
These observations suggest that some differences between the
SIVmac239 and HIV-1 gp120 subunits in the assembled envelope
glycoprotein trimer exist, as summarized in Fig. 9. By virtue of the
Phe 43 cavity-filling Trp 375, SIVmac239 gp120 has a strong pro-
pensity to assume the CD4-bound conformation. Since prema-
ture movement into the CD4-bound conformation can have neg-
ative consequences (gp120 shedding, exposure of neutralization
epitopes, and rapidly decaying intermediate states), this propen-
sity in SIVmac239 gp120 is compensated by the strong contribu-
tion of the inner domain layer 1 to the association of gp120 with
the trimer. With Trp 375 filling the Phe 43 cavity, layer 1-layer 2
interactionsmakeminimal contributions toCD4 binding. In con-
trast, inHIV-1 gp120, which lacks a Phe 43 cavity-filling residue at
position 375, the propensity to assume the CD4-bound confor-
mation is lower than that in SIVmac239 gp120. The association of
HIV-1 gp120with the unliganded trimer is adequatelymaintained
by the N/C termini and the inner domain -sandwich and layer 2.
In HIV-1, therefore, the major function of layer 1 is to promoteFIG 7 Functionality of SIVmac239 gp120 envelope glycoprotein variants. (A)
Cell-cell fusion ability was assessed by coincubation of 293T cells expressing
the envelope glycoprotein variants with the reporter TZM-bl cells for 6 h at
37°C. The activities of the mutant envelope glycoproteins were normalized to
that of the wild-type (wt) envelope glycoproteins. The results shown represent
the means
 SEM obtained from at least three independent experiments. (B)
Relative infectivity was assessed by incubating Cf2Th-CD4/CCR5 cells with
similar amounts of recombinant HIV-1 pseudotyped with wild-type and mu-
tant SIVmac239 envelope glycoproteins, normalized according to reverse
transcriptase. Data shown represent the means
 SEM obtained from at least
three independent experiments. (C) The cell surface expression of the wt and
fusion-defective SIVmac239 P76A andD78A envelope glycoproteinswasmea-
sured by a cell-based ELISA. The results are normalized to the value obtained
for the wt SIVmac239 envelope glycoproteins and represent the average for at
least three independent experiments
 SD performed in quadruplicate.
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high-affinity CD4 binding by solidifying the interactionwith layer
2 and decreasing the off rate of CD4.
The SIVmac239 envelope glycoproteins were chosen for this
study because they exhibit a level of CD4 dependence compa-
rable to that of the previously studied HIV-1YU2 envelope gly-
coproteins (5, 21). However, SIVmac239 is more CD4 depen-
dent, more neutralization resistant, and less able to infect
monkey macrophages than most other members of the
SIVsmm clade. How generalizable are the results that we ob-
tained with the SIVmac239 envelope glycoproteins? First, de-
spite the similar levels of CD4 dependence of the SIVmac239
and HIV-1YU2 envelope glycoproteins, the phenotypes of the
gp120 inner domain layer 1 mutants differed. Thus, layer 1
function in other members of the SIVsmm/HIV-2 clade, which
are less dependent on CD4 than either SIVmac239 or HIV-1YU2
(5), is also expected to differ from that of HIV-1. Second, the
SIVmac239 gp120 residues identified in this study as important
for gp120-trimer association and CD4 binding are well con-
served in all SIVsmm andHIV-2 strains. Therefore, all SIVsmm
and HIV-2 gp120 envelope glycoproteins likely share common
structural and functional inner domain elements. However,
although the Phe 43 cavity-filling tryptophan 375 residue is
found in the gp120 glycoproteins of HIV-2 and most monkey
SIVs, differences in the inner domain layer 1 and layer 2 se-
FIG 8 Effect of sCD4 on infection of CD4	CCR5	 and CD4CCR5	 cells. The amounts of recombinant luciferase-expressing HIV-1 pseudotyped with the wt
and mutant SIVmac239 envelope glycoproteins were normalized according to reverse transcriptase. Viruses were incubated at 37°C with increasing concentra-
tions of sCD4 (0 to 200 nM) for 1 h prior to addition of Cf2Th-CD4/CCR5 (A) or Cf2Th-CCR5 (B) target cells. Luciferase activity was measured after a 48-h
incubation at 37°C. In panel A, the level of infection after incubationwith sCD4 relative to the level observed for the same virus without sCD4 treatment is shown.
In panel B, the absolute levels of infection in relative luciferase units are shown. The results represent the averages (
 SD) from three independent experiments
performed in triplicate.
FIG 9 Summary of functional differences between HIV-1 and SIVmac239 gp120 glycoproteins. One of the three gp120 subunits of the SIVmac239 and HIV-1
envelope glycoprotein trimer is depicted. In the orientation shown, the trimer axis runs vertically on the left of each figure and the viral membrane is at the top
of the figure. The gp120 N and C termini are colored cyan, the -sandwich is red, layer 1 is magenta, layer 2 is green, layer 3 is ochre, and the outer domain (OD)
is yellow. The Trp 375 side chain that fills the Phe 43 cavity of SIV gp120 is depicted. The major contributions of the gp120 N and C termini, the inner domain
(the -sandwich, layer 1, and layer 2), and the Phe 43 cavity to gp120-trimer association and/or CD4 binding are shown. Note that the contribution of the filled
SIVmac239 gp120 Phe 43 cavity to CD4 binding is lacking in HIV-1 gp120; this lack is compensated by a contribution of the HIV-1 gp120 inner domain layer 1
to CD4 binding. In contrast, the inner domain layer 1 of SIVmac239 gp120makes a larger contribution to gp120-trimer association than layer 1 of HIV-1 gp120.
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quences occur among the distinct SIV lineages associated with
different African monkey species. Additional studies will be
required to determine the functional implications of these
layer 1/layer 2 differences in SIV lineages other than the HIV-
2/SIVsmm clade.
What was the sequence of events during PIV evolution that led
to the observed changes in the gp120 inner domain and Phe 43
cavity? Based on our current understanding of PIV evolution (66)
and the patterns observed in Fig. 3, we can suggest a model. The
ancestral pool of indigenous SIVs likely had short inner domain
layer 1 structures and a Phe 43 cavity filled with a tryptophan
residue. At some point in time and for reasons that are unknown,
the SIVgsn/SIVmus/SIVmon gp120 glycoproteins evolved longer
disulfide loops in layer 1without changing the Phe 43 cavity-filling
tryptophan residue. The longer layer 1 sequences in the gp120
glycoproteins of SIVgsn/SIVmus/SIVmon are not likely to result
in an extension of the 0 helix, in contrast to the situation in
HIV-1 gp120 (54). This assertion is supported by the presence of
Pro 65 and Gly 66 residues, both unfavorable for stable helix for-
mation, in layer 1 of the SIVgsn/SIVmus/SIVmon gp120 inner
domains. Nonetheless, some advantage resulted in fixation of the
longer layer 1 in the gp120 glycoproteins of these SIVs. SIVgsn,
SIVmus, and SIVmon infect three closely related Cercopithecus
species (C. nictitans, C. cephus,, and C. mona, respectively), which
are hunted by chimpanzees in central Africa. Chimpanzees are
thought to have become infected with one of these SIVs, which,
through a recombination event with a coinfecting SIVrcm, sup-
plied the env gene to the SIVcpz precursor of HIV-1 (4, 66). With
the evolution of SIVcpz, His 66 makes its first appearance in the
elongated layer 1, allowing stacking interactions to occur with the
preexisting Pro 212 in layer 2. Thus, by the time SIVcpz variants
became indigenous in African chimpanzees, the ability of layer
1-layer 2 interactions to bolster CD4 bindingwas established. This
may have relaxed the evolutionary pressure to maintain a trypto-
phan 375 residue in the Phe 43 cavity, as evidenced by the prefer-
ence in SIVcpzPtt, SIVgor, and HIV-1 strains for residues other
than tryptophan at position 375. Subsequent adaptation in hu-
mans further influenced the identity of residue 375. The less suc-
cessful group N and group O HIV-1 strains retain the large resi-
dues at position 375 found in their respective chimpanzee and
gorilla SIV ancestors. The extremely successful group M HIV-1
evolved an empty Phe 43 cavity. Thus, a series of sequential struc-
tural changes in the gp120 inner domain and Phe 43 cavity appar-
ently provided the circumstances conducive to the evolution of a
group M HIV-1 envelope glycoprotein well suited for transmis-
sion and spread in humans.
The different arrangements of the Phe 43 cavity and inner do-
main of HIV-1 and SIVsmm gp120 glycoproteins helps to explain
why SIVsmm envelope glycoproteins are generally less dependent
on CD4 for CCR5 interaction, are able to infect cells that express
low levels of CD4, and can maintain a long-lived sCD4-activated
state (17, 50, 58–61, 65). What biological necessities shaped the
divergent evolution of these HIV-1 and SIV gp120 elements? The
very low level of CD4 expression on the surface of tissue macro-
phages of monkeys (5, 51) may provide selective pressure on the
SIV envelope glycoproteins to achieve and maintain the CD4-
bound conformation after engaging CD4 at low stoichiometry.
Indeed, the nearly undetectable levels of CD4 expression onmon-
key macrophages have been shown to represent the major factor
limiting their infection by T cell-line-tropic SIVsmm strains and,
notably, bymacrophage-tropicHV-1 strains (5, 51). The ability of
the latter viruses to infect primary human macrophages suggests
that human macrophages targeted for HIV-1 infection must have
higher levels of surface CD4 available for envelope glycoprotein
interaction than primary macrophages from monkeys. Freed of
the necessity to maintain the ability to infect cells with extremely
low levels of CD4 expression, HIV-1may have taken advantage of
the benefits of avoiding the CD4-bound conformation. Transmit-
ted/founderHIV-1 typically retains the ability to infect T lympho-
cytes but notmonocytes/macrophages (53). Thus, HIV-1 tropism
for cells with low CD4 levels, like monocytes/macrophages and
microglia cells, may need to be acquired as the virus evolves in
particular tissue compartments, such as the central nervous sys-
tem (16, 26, 49, 55, 56, 69). Anunderstanding of PIV adaptation to
species-specific environments may assist efforts to intervene in
virus transmission, spreadwithin the infected host, and pathogen-
esis.
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